India  

Covaxin

Vaccine against COVID-19

Covaxin    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Covaxin: Vaccine against COVID-19
Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

1
shares
ShareTweetSavePostSend
 
Bharat Biotech completes trials for India's first intranasal Covid-19 vaccine | Oneindia News*News [Video]

Bharat Biotech completes trials for India's first intranasal Covid-19 vaccine | Oneindia News*News

Today, Bharat Biotech International Limited said that it has completed the clinical development for phase III trials and booster doses for the BBV154 (Covaxin) intranasal Covid-19..

Credit: Oneindia     Duration: 01:52Published

You Might Like


Govt: Sputnik V recipients can take Covishield, Covaxin booster


IndiaTimes - Published

Corbevax gets nod as booster after Covishield, Covaxin shots


IndiaTimes - Published

India to start Covid mix-and-match booster vaccines on Friday

India said on Wednesday that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's..
IndiaTimes - Published

Biological E's Corbevax approved as booster dose for adults vaccinated with Covaxin, Covishield

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in India.
DNA - Published Also reported by •IndiaTimes

Govt nod for Corbevax as booster for adults vaccinated with Covishield, Covaxin soon


IndiaTimes - Published

Japan allows Covaxin boosted travellers to visit country


IndiaTimes - Published

Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 years

Prime Minister Narendra Modi emphasised that all eligible children get the Covid-19 vaccine as soon as possible via "special programmes" in schools.
DNA - Published

NTAGI approves Corbevax, Covaxin for 5-12 years age group: Sources


IndiaTimes - Published

Corbevax being considered as booster dose for Covishield, Covaxin jabbed people

NTAGI is considering using Corbevax as a booster vaccination against Covid-19.
DNA - Published

Covaxin safe for 2-18 age group: BB study

It conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in children and adolescents in the 2-18 years of age group between..
IndiaTimes - Published

Covaxin booster beats back Delta, Omicron variants: NIV

The researchers compared the efficacy of Covaxin after the second and third doses against the Delta variant, and also studied its efficacy against the Omicron variants in a Syrian hamster model.
IndiaTimes - Published

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants: ICMR study

The findings of the study by ICMR have been published on Tuesday on bioRxiv, a pre-print server and have not been peer-reviewed.
DNA - Published Also reported by •IndiaTimes

NTAGI to discuss allowing Corbevax as booster shot for Covishield, Covaxin recipients: Sources

Allowing Biological E's Corbevax as a booster for those fully vaccinated against Covid-19 with either Covishield or Covaxin and reducing the gap between the second dose and the precaution dose of the..
IndiaTimes - Published

FDA lifts hold on Covaxin's clinical trials in US

The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by..
IndiaTimes - Published

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in..
IndiaTimes - Published

Corbevax maker seeks emergency use approval as booster jab for adults vaccinated with Covishield, Covaxin

There were 416 patients aged 18 to 80 who got two doses of Covaxin or Covishield, the last one six months before the Corbevax booster.
DNA - Published

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI...
IndiaTimes - Published

Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world..
IndiaTimes - Published

DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12

The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between the age of six and 12. A Subject Expert..
IndiaTimes - Published Also reported by •DNA

DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age group

The Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat Biotech's Covaxin has got nod for use in..
IndiaTimes - Published

Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12

The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children aged..
IndiaTimes - Published

Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold

The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA. Bharat Biotech's partner for US and Canada for Covaxin, the FDA's..
IndiaTimes - Published

Covid Update: Get Covaxin, Covishield at Rs 225

Price slash of Covaxin and Covishield was announced after the government allowed all above 18 years of age can get booster dose from April 10.
DNA - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech


IndiaTimes - Published

High immune response to Covid variants in breakthrough cases after 2 Covaxin jabs: ICMR study

In a recent ICMR study, breakthrough cases after full vaccination with Covaxin have shown a significant increase in the immune response against coronavirus' variants of concern -- Beta, Delta and..
IndiaTimes - Published

'Amid drop in demand, Bharat Biotech slowed Covaxin production since February'


IndiaTimes - Published

WHO suspension not to impact Covaxin as no supplies to any UN agency yet


IndiaTimes - Published

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and..
IndiaTimes - Published

SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group

Covovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.
DNA - Published

WHO suspends Covaxin supply, rules out safety fears


IndiaTimes - Published

WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilities


IndiaTimes - Published

Slowing down Covaxin output across plants for maintenance, process & facility optimisation: Bharat Biotech

Bharat Biotech on Friday announced the temporary slowing down of production of its Covid-19 vaccine Covaxin across its manufacturing facilities as it has completed its supply obligations to procurement..
IndiaTimes - Published

ICMR study shows increase in antibodies after receiving Covaxin booster dose, says MoS Health

International data available on booster doses of AstraZeneca & Covishield suggests 3 to 4 fold increase in antibody levels after their administration.
DNA - Published

Haffkine's rollout of Covaxin not likely till end of this year


IndiaTimes - Published

Mixing Covishield & Covaxin gives better immunity: ICMR


IndiaTimes - Published

Qatar sets ‘immunity validity period’: 9 months for Covishield & 6 months for Covaxin last shot


IndiaTimes - Published

USFDA paves way for Covaxin trials in US


IndiaTimes - Published

USFDA lifts clinical hold on Ocugen's IND application for Covaxin paving way for its evaluation for US market


IndiaTimes - Published

Covaxin granted Emergency Use Listing in 13 nations as on Jan 31 according to WHO: Govt

Covaxin has been granted Emergency Use Listing (EUL) in 13 countries as on January 31 according to the WHO, Minister of State for Health Bharati Pravin Pawar informed the Lok Sabha on Friday...
IndiaTimes - Published

From free recharge for COVID vaccine to Neeraj Chopra's pro-farmer tweet: Top 'Fake News' stories of 2021

The biggest fake news stories that fooled people included claims of cow serum in Covaxin, outrageous RBI scheme and the annual false Ratan Tata quote.
DNA - Published

Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech


IndiaTimes - Published

States prepare to vaccinate teenagers in age group of 15-18 years from January 3

Registration on CoWIN portal will begin from January 1 and on-site registrations will start from January 3. Only Covaxin will be used for vaccination.
DNA - Published

'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelines

Bharat Biotech's Covaxin has been granted approval for restricted use in an emergency situation in the age group between 12 and 18 years.
DNA - Published

Covid vaccination: Children between 15-18 years can register on CoWin from Jan 1, on-site from Jan 3

Children between 15 and 18 years can register online on CoWin from January 1 or onsite at vaccination centres to receive Covaxin shots from January 3. They can register themselves online through an..
IndiaTimes - Published

Covaxin only vaccine option for children in 15-18 years age group: Govt


IndiaTimes - Published


 Page 1  〉